

FIGURES

	Country	Sex	Age (years)	Confirmed COVID-19	Serious	Therapy start date	Start of most recent course	Year 1 course complete	Year 2 course complete	Last lymphocyte count (G/L)	Most recent lymphocyte count (date)	COVID-19 onset (date)	Time from most recent course to COVID-19 onset (days)	COVID-19 recovery (date)	Last status
1	Norway	F	35	Y	N	01/02/19	17/02/20	Y	N	1.1	NR	08/03/20	20	18/03/20	Recovered
2	Germany	M	59	Y	Y	10/03/20	10/03/20	N	N	0.24	NR	Mar-20	NR	NA	Recovering
3	France	F	57	Y	Y	08/10/18	01/10/19	Y	Y	0.34	NR	29/03/20	115	28/04/20	Recovered
4	Netherlands	M	49	Y	N	18/11/19	18/11/19	Y	N	0.87	13/01/20	01/03/20	104	NA	Recovered
5	UK	M	29	N	N	01/10/18	01/10/19	Y	Y	0.5	18/03/20	24/03/20	175	NA	Recovered
6	UK	F	38	N	N	09/11/18	15/11/19	Y	Y	1.2	26/01/20	13/03/20	119	NA	Recovered
7	UK	F	53	N	N	NR	NR	Y	Y	0.7	Mar-20	NR	NR	NA	Recovered

F, female; M, male; N, no; NA, not available; NR, not reported; Y, yes

Figure 1

Figure 2




Figure 3




Figure 4





Figure 5



5/24

(Shingrix – pref. 2 months apart – flexibility: up to 6 months apart)

MAVENCLAD: (1) Week 1 (or Month 1, week 1), (2) Week 5 (or Month 2, week 1), (3) Week 49 (or Month 13, week 1), (4) Week 53 (or Month 14, week 1)
Vaccination: 1st dose: Week 60-88, pref. Week 64-80, 2nd dose: Week 68-96, pref. Week 72-88




Figure 6

Figure 7.1:
Patient – Spain 2





Figure 7.2:
Patient – Spain 3



Legend

- MAV: Mavenclad
- Scr: Screening
- ALC: Approximate lymphocyte count
- W: weeks before/after Mavenclad treatment initiation
-  Vaccination
-  Mavenclad tablets course 1 / course 2

Figure 7

Figure 8.1:
Patient – Canada 1




Figure 8.2:
Patient – Spain 1




Figure 8

Figure 9.1:
Patient – Finland 1




Figure 9.2:
Patient – France 1




Figure 9

Figure 10.1:
Patient – Australia 1




Figure 10.2:
Patient – Finland 2




Figure 10

Figure 11.1:
Patient – Germany 1




Figure 11.2:
Patient – UK 2




Figure 11

12/24

Figure 12.1
Patient – UK 1




Figure 12.2:
Patient – France 2




Figure 12

Figure 13.1:
Patient – Canada VZV




Figure 13.2:
Patient – Finland VZV





Figure 13

Figure 14:
Patient –Australia VZV



Legend

MAV: Mavalclad

Scr: Screening


ALC: Approximate lymphocyte count

W: weeks before/after Mavalclad treatment initiation

 Vaccination

 Mavalclad tablets course 1 / course 2

Figure 14



2020-2021 Influenza Vaccine Composition	
It is recommended that egg based quadrivalent vaccines for use in the 2020-2021 northern hemisphere influenza season contain the following:	
an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus; an A/Hong Kong/2671/2019 (H3N2)-like virus; a B/Washington/02/2019 (B/Victoria lineage)-like virus; and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).	
Cell- or recombinant-based quadrivalent vaccines for use in the 2020-2021:	
an A/Hawaii/70/2019 (H1N1)pdm09-like virus; an A/Hong Kong/45/2019 (H3N2)-like virus; a B/Washington/02/2019 (B/Victoria lineage)-like virus; and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).	
2019-2020 Influenza Vaccine Composition	
It is recommended that egg based quadrivalent vaccines for use in the 2019-2020 northern hemisphere influenza season contain the following:	
an A/Brisbane/02/2018 (H1N1)pdm09-like virus; an A/Kansas/14/2017 (H3N2)-like virus; a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).	
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019-2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.	
2018-2019 Influenza Vaccine Composition	
It is recommended by WHO that quadrivalent vaccines for use in the 2018-2019 northern hemisphere influenza season contain the following:	
A/Michigan/45/2015 (H1N1)pdm09-like virus; A/Singapore/INF15H-16-0019/2015 (H3N2)-like virus; B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and B/Phuket/3073/2013-like virus (Yamagata lineage)	
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.	
2017-2018 Influenza Vaccine Composition	
All 2017-18 influenza vaccines licensed in the United States will contain hemagglutinin (HA) derived from influenza viruses antigenically similar to those recommended by FDA.	
2017-18 trivalent vaccines:	
A/Michigan/45/2015 (H1N1)pdm09-like virus; A/Hong Kong/4801/2014 (H3N2)-like virus; B/Brisbane/60/2008-like virus (Victoria lineage)	
2017-18 quadrivalent vaccines:	
the same three HA antigens as trivalent vaccines, plus B/Phuket/3073/2013-like virus (Yamagata lineage)	

Figure 16




Figure 17

Follow-up after COVID-19 vaccination in MAVENCLAD®-treated MS patients




Figure 18

COVID-19, coronavirus disease 2019; FU, follow up; SD, standard deviation; VAC, vaccination.




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24